+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 5Years - 17Years
All Genders
ID07630714

Evaluating Subcutaneous Anifrolumab in Children Aged 5 to under 18 with Moderate to Severe Systemic Lupus Erythematosus Pharmacokinetics, Pharmacodynamics, and Safety Study

Led by AstraZeneca · Updated on 2026-10-28

24

Participants Needed

39

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in children aged 5 to under 18 years with moderate to severe systemic lupus erythematosus SLE who are receiving standard of care treatments. This open-label, multicenter Phase II study aims to understand how the medication behaves in the body and its effects in this pediatric population. The study includes screening for up to 35 days followed by a 12-week treatment period where anifrolumab is given as a subcutaneous injection using an accessorized pre-filled syringe. There is an optional 12-week period to adjust the dosing regimen if needed, and participants may enter an optional treatment extension lasting up to 40 weeks. After treatment, a 12-week safety follow-up period is conducted. Participants are grouped into two cohorts based on body weight those weighing more than 40 kg and those between 15 and 40 kg, both receiving the study drug via injection. Participants will undergo various assessments including blood tests to measure drug levels and immune response markers at multiple time points, especially during the first days and up to week 12. Researchers will monitor safety and immune system activity through laboratory tests and clinical evaluations throughout the study and follow-up periods. The total duration of participation may extend over several months depending on whether participants enter the extension period, allowing detailed observation of treatment effects and safety.

CONDITIONS

Brief Title

A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus

Research Team

A

AstraZeneca Clinical Study Information Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here